0001209191-19-021883.txt : 20190329
0001209191-19-021883.hdr.sgml : 20190329
20190329201345
ACCESSION NUMBER: 0001209191-19-021883
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190327
FILED AS OF DATE: 20190329
DATE AS OF CHANGE: 20190329
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BRYANT DOUGLAS C
CENTRAL INDEX KEY: 0001406652
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-10961
FILM NUMBER: 19718448
MAIL ADDRESS:
STREET 1: C/O QUIDEL CORPORATION
STREET 2: 12544 HIGH BLUFF DRIVE, SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: QUIDEL CORP /DE/
CENTRAL INDEX KEY: 0000353569
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 942573850
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12544 HIGH BLUFF DRIVE
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: 8585521100
MAIL ADDRESS:
STREET 1: 12544 HIGH BLUFF DRIVE
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
FORMER COMPANY:
FORMER CONFORMED NAME: MONOCLONAL ANTIBODIES INC /DE/
DATE OF NAME CHANGE: 19910210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-03-27
0
0000353569
QUIDEL CORP /DE/
QDEL
0001406652
BRYANT DOUGLAS C
12544 HIGH BLUFF DRIVE, SUITE 200
SAN DIEGO
CA
92130
1
1
0
0
President & CEO
Common Stock
2019-03-27
4
M
0
795
12.63
A
302237
D
Common Stock
2019-03-27
4
S
0
795
65.03
D
301442
D
Common Stock
2019-03-28
4
M
0
1335
12.63
A
302777
D
Common Stock
2019-03-28
4
S
0
1335
65.062
D
301442
D
Common Stock
2019-03-29
4
M
0
23120
12.63
A
324562
D
Common Stock
2019-03-29
4
S
0
23120
65.696
D
301442
D
Non-Qualified Stock Option
12.63
2019-03-27
4
M
0
795
0.00
D
2021-03-02
Common Stock
795
30293
D
Non-Qualified Stock Options
12.63
2019-03-28
4
M
0
1335
0.00
D
2021-03-02
Common Stock
1335
28958
D
Non-Qualified Stock Options
12.63
2019-03-29
4
M
0
23120
0.00
D
2021-03-02
Common Stock
23120
5838
D
The weighted average sale price for these transactions was $65.03 per share, with a range of $65.00 to $65.11. Upon request, the Reporting Person hereby undertakes to provide to staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder, the full information regarding the number of shares sold at each separate price.
The weighted average sale price for these transactions was $65.062 per share, with a range of $65.03 to $65.08. Upon request, the Reporting Person hereby undertakes to provide to staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder, the full information regarding the number of shares sold at each separate price.
The weighted average sale price for these transactions was $65.696 per share, with a range of $65.38 to $66.29. Upon request, the Reporting Person hereby undertakes to provide to staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder, the full information regarding the number of shares sold at each separate price.
42,959 shares vested on 03/02/2013; 21,479 shares vested on 03/02/2014; 21,480 shares vested on 03/02/2015.
All transactions reported herein were effected pursuant to a pre-established 10b5-1 trading plan.
Robert J. Bujarski, attorney-in-fact for Douglas C. Bryant
2019-03-29